<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204529</url>
  </required_header>
  <id_info>
    <org_study_id>ML17840</org_study_id>
    <nct_id>NCT00204529</nct_id>
  </id_info>
  <brief_title>Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB</brief_title>
  <official_title>Randomized, Multicenter, Open Label Study to Compare the Efficacy and Tolerability of Pegylated Interferon-alpha-2 (PEG-IFN) to 'Low-dose' Interferon-alpha-2a in Patients With Malignant Melanoma in Stages IIA (T3a) - IIIB (AJCC 2002)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dermatologic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of adjuvant treatment with
      pegylated interferon-α-2a (PEG-IFN) vs. 'low dose' interferon-α-2a in patients with malignant
      melanoma in stage IIA (T3a) - IIIB.

      A total of 880 will be randomized up to three months after first surgical management of their
      melanoma to either: PEG-IFN-α-2a or low-dose interferon-α-2a.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2004</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to distant metastasis</measure>
    <time_frame>From date of randomization until the date of first documented distant metastases or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Measured at different visits (week 0, week 12, month 3, month 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Grade of Adverse Events</measure>
    <time_frame>Measured at every visit (week 4, week 8, week 12, month 3, month 6 and every 3 months during therapy)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">901</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>PegIFN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegylated interferon-alpha-2a</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>interferon-alpha-2a</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon-alpha-2a</intervention_name>
    <arm_group_label>PegIFN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon-alpha-2a</intervention_name>
    <arm_group_label>IFN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven cutaneous melanoma

          -  ≥ 18 years of age and &lt; 75 years of age

          -  Have confirmed stage IIa (T3a), IIB, IIC, IIIA or IIIB (AJCC 2002) melanoma (lymph
             node staging either per sentinel node biopsy or elective lymph node dissection)

          -  Have a Karnofsky performance status of ≥ 80%

          -  Negative pregnancy test

          -  Start of therapy within three months after surgery

          -  Informed consent

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Unwillingness or inability to employ an effective barrier method of birth control
             throughout the study and for up to 3 months after end of treatment in female or male
             patients

          -  Mucous membrane or ocular melanoma

          -  Any evidence of distant metastasis (CT-scan of brain, Chest X ray or CT, abdominal
             ultrasound or CT and ultrasound of regional lymph nodes at screening)

          -  Patients who have received chemotherapy or vaccines for melanoma

          -  Patients with tumor progression under a previous adjuvant interferon therapy or within
             three months after termination of interferon therapy (patients previously receiving
             adjuvant interferon therapy in another tumor stage without disease progression may be
             included)

          -  History of any other malignancy within the last ten years (except basal cell carcinoma
             or squamous cell carcinoma of the skin and carcinoma in situ of the cervix)

          -  Patients with severe cardiac disease (e.g. NYHA Functional Class III or IV, myocardial
             infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment,
             unstable angina), severe liver disease or severe renal disease.

          -  ALAT or ASAT &gt; 2 x ULN

          -  Bilirubin &gt; 2 x ULN

          -  Creatinine &gt; 2 x ULN

          -  Patients who have a history of depression or other psychiatric diseases requiring
             hospitalisation

          -  Patients with seizure disorders requiring anticonvulsant therapy

          -  Any of the following abnormal baseline hematologic/laboratory values:

               -  Hb &lt;10g/dl

               -  WBC &lt;3.0 x 109 /l

               -  Platelets &lt;100x109/l

               -  Neutrophils &lt; 1.5 x 109/l

          -  History or presence of autoimmune disease (i.e. autoimmune hepatitis, thyroid
             auto-immune dysfunction, systemic lupus erythematodes)

          -  Unwilling or unable to comply with the requirements of the protocol for the duration
             of the study

          -  Known infection with HBV, HCV, HIV

          -  Evidence of allergy or hypersensitivity against IFN or pegylated interferon

          -  Thyroid disease poorly controlled on prescribed medications

          -  Systemic corticosteroid therapy for any reason (&gt;1 month)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Garbe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Cancer Program, Department of Dermatology, University of Tübingen, Liebermeisterstr. 20, 72076 Tübingen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hubert Pehamberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, University Hospital Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arbeitsgemeinschaft Dermatologische Onkologie, Skin Cancer Program, Department of Dermatology, University of Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>BW</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.hauttumorzentrum.de</url>
    <description>Synopsis of study protocol</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Thomas Eigentler</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>malignant melanoma</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>Adjuvants, Immunologic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

